AVEO Oncology Marks Milestone with First Patient Dosing in AML Study of Ficlatuzumab

AVEO Oncology Celebrates Major Milestone in AML Treatment Development

AVEO Oncology, a company that is a part of LG Chem, has recently announced a significant step forward in the treatment of acute myeloid leukemia (AML). The company reported that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating the effectiveness of ficlatuzumab, a novel treatment option. This clinical trial aims to explore the use of ficlatuzumab in combination with azacitidine and venetoclax for patients aged 60 years and older who have untreated AML. This initiative is made possible through a partnership with Blood Cancer United, a prominent nonprofit organization focused on blood cancer research and patient support.

The clinical trial being conducted is part of the 'Beat AML Master Clinical Trial', which is recognized as a groundbreaking effort to improve treatment strategies for blood cancers. This trial uniquely assesses multiple therapies across various study arms simultaneously. The collaboration showcases a significant stride toward operational excellence in cancer therapy research. The involvement of Blood Cancer United highlights the organization's commitment to advancing clinical outcomes for those battling blood cancer.

In this Phase 1b/2 trial, researchers will evaluate various factors, including safety, pharmacokinetics (the metabolic process of drugs), pharmacodynamics (the biochemical and physiological effects of drugs), and preliminary efficacy. The underlying science of ficlatuzumab revolves around its aim to inhibit the hepatocyte growth factor (HGF), a crucial player that tends to promote cancer cell growth through its signaling pathway with the c-Met receptor.

AVEO's previous trials indicated that ficlatuzumab, especially when combined with traditional chemotherapy agent cytarabine, has shown a notably favorable safety profile while also revealing promising signs of clinical activity. These findings have laid the groundwork for further studies focused on patients who may not be suitable candidates for conventional intensive therapies.

Michael P. Bailey, the President and CEO of AVEO, expressed excitement over this developmental milestone, stating that it represents a shared dedication to enhancing patient outcomes through innovative clinical research. He emphasized the importance of collaborative partnerships in this research domain, especially concerning areas with high unmet medical needs.

Lore Gruenbaum, Ph.D., the Chief Scientific Officer of Blood Cancer United, also commented, noting that their work aims to reshape treatment paradigms for AML. The implementation of strategic partnerships such as the one with AVEO plays a pivotal role in this transformative journey.

Background on AVEO and Their Research Initiatives

AVEO Pharmaceuticals is acclaimed for its commitment to delivering innovative cancer care solutions. The company markets FOTIVDA (tivozanib) in the United States for renal cell carcinoma and has ongoing research programs targeting various cancers with high unmet demands, such as head and neck squamous cell carcinoma and cancer cachexia.

AVEO became a part of LG Chem Life Sciences on January 19, 2023, and continues scaling its operations focused on developing pioneering pharmaceutical therapies.

Blood Cancer United and Its Role

Blood Cancer United is a leading nonprofit aimed at supporting patients with blood cancers. They conduct extensive research and foster advocacy to improve the lives of those affected. Their ambitious campaign - the Beat AML Master Clinical Trial - has garnered a strong reputation for employing advanced genomic technology to tailor treatments based on individual genetic profiles.

Ficlatuzumab: A Promising New Therapy

Ficlatuzumab, once known as AV-299, is a humanized monoclonal antibody that revolutionizes treatment pathways by effectively blocking HGF signaling, which is often hijacked by cancer cells to proliferate. The FDA has recognized its potential, fast tracking the development for head and neck cancer treatments, solidifying its promise within the wider cancer therapy landscape.

In summary, AVEO Oncology's recent milestones signify not only advancements in AML treatment but also the value of collaboration in enhancing patient care in oncology. As the clinical trial progresses, the anticipation for ficlatuzumab's broader applications in cancer treatment continues to grow.